Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Sep 18, 2022 6:40pm
216 Views
Post# 34970201

RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo Clinic

RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo ClinicBarriers such as tumor heterogeneity and T cell exhaustion have exposed the weaknesses of various mono-immunotherapeutic approaches to GBM, including CAR T cell and checkpoint blockade strategies.

ONCY's pelareorep to (1) dramatically increase CAR-T cell persistence, (2) reverse an immunosuppressive tumor microenvironment (TME) and (3) to overcome the attenuation of antigen escape induced by T-cell immunotherapy is showing to be a significant benefit of this pelareorep + CAR-T  immuno-oncology (I/O) combination therapy, particularly after a subsequent intravenous boost of pelareorep is given following the initial dose of pelareorep + CAR-T therapy.

Combining these three (3) complementary strategies, can proffer a rational means of mitigating these barriers and advancing therapeutic successes against GBM, pancreatic cancer and other solid tumors.
<< Previous
Bullboard Posts
Next >>